Suppr超能文献

复发性流产与低滴度抗磷脂抗体。

Recurrent miscarriage and low-titer antiphospholipid antibodies.

机构信息

Department of Rheumatology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

出版信息

Clin Rheumatol. 2024 Apr;43(4):1327-1334. doi: 10.1007/s10067-023-06843-x. Epub 2024 Feb 26.

Abstract

OBJECTIVE

To evaluate the clinical features and pregnancy outcomes in patients experiencing recurrent miscarriage (RM) with either low-titer or medium-high titer positivity of antiphospholipid antibodies (aPL).

METHODS

A retrospective review of medical records was conducted for patients with aPL positivity and recurrent miscarriage between 2018 and 2022. The clinical features, treatment strategies, outcomes were compared between the patients with low (n = 92) and medium (n = 32) titer of aPL.

RESULTS

A total of 118 patients, resulting in 124 obstetric episodes (pregnancies), with a mean age of 33. 15 ± 4.56 and 31.47 ± 4.41 years between the two groups. The low-titer group exhibited a higher frequency of anti-cardiolipin antibodies IgM (P < 0.001), whereas the medium-high titer group demonstrated a higher frequency of anti-β2-glycoprotein 1 antibodies IgG (P < 0.001) and IgM (P = 0.032). Moreover, the medium-high titer group displayed a significantly elevated erythrocyte sedimentation rate compared to the low-titer group (P < 0.05). In the low-titer group, 71 patients (77.2%) received appropriate treatment, resulting in 48 live births (67.6%) and 23 repeat abortions (32.4%). In the medium-high titer group, 29 patients (90.6%) received relevant treatment, leading to 23 live births (79.3%) and 6 repeat abortions (20.7%). No significant differences were observed in live births or maternal-fetal complications between the two groups (all P > 0.05).

CONCLUSION

Noteworthy distinctions in laboratory parameters were identified between the low-titer and medium-high titer groups. However, when appropriately treated, the fetal-maternal outcomes were comparable in both groups. Timely intervention by clinicians is imperative to enhance pregnancy outcomes in patients experiencing recurrent miscarriage with low levels of aPL. Key Points • This study challenges the conventional belief that only the higher antiphospholipid antibodies (aPL) titers directly correlated with worse pregnancy outcomes, which emphasized the importance of patients with low titer positive aPL-positive RM. • The results underscore the need for timely intervention in women with low titer aPL-positive RM, as it leads to favorable maternal-fetal outcomes.

摘要

目的

评估抗磷脂抗体(aPL)低滴度或中高滴度阳性的复发性流产(RM)患者的临床特征和妊娠结局。

方法

对 2018 年至 2022 年间 aPL 阳性和复发性流产的患者进行了病历回顾。比较了低滴度(n=92)和中高滴度(n=32)aPL 患者的临床特征、治疗策略和结局。

结果

共 118 例患者,124 次产科分娩(妊娠),两组平均年龄分别为 33.15±4.56 岁和 31.47±4.41 岁。低滴度组抗心磷脂抗体 IgM 频率更高(P<0.001),而中高滴度组抗β2-糖蛋白 1 抗体 IgG(P<0.001)和 IgM(P=0.032)频率更高。此外,中高滴度组红细胞沉降率明显高于低滴度组(P<0.05)。低滴度组 71 例(77.2%)患者接受了适当的治疗,48 例活产(67.6%),23 例复发性流产(32.4%)。中高滴度组 29 例(90.6%)患者接受了相关治疗,23 例活产(79.3%),6 例复发性流产(20.7%)。两组活产儿或母婴并发症无显著性差异(均 P>0.05)。

结论

低滴度组和中高滴度组实验室参数存在显著差异。然而,适当治疗后,两组胎儿-母体结局相当。临床医生及时干预对改善低水平 aPL 阳性复发性流产患者的妊娠结局至关重要。

关键点

  1. 本研究挑战了传统观念,即只有更高的抗磷脂抗体(aPL)滴度与更差的妊娠结局直接相关,强调了低滴度阳性 aPL 阳性 RM 患者的重要性。

  2. 结果强调了及时干预低滴度 aPL 阳性 RM 妇女的必要性,因为这会导致有利的母婴结局。

相似文献

1
Recurrent miscarriage and low-titer antiphospholipid antibodies.
Clin Rheumatol. 2024 Apr;43(4):1327-1334. doi: 10.1007/s10067-023-06843-x. Epub 2024 Feb 26.
4
Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study.
Am J Obstet Gynecol. 2017 May;216(5):525.e1-525.e12. doi: 10.1016/j.ajog.2017.01.026. Epub 2017 Jan 30.
6
Anti-beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage.
Br J Haematol. 2001 Jun;113(4):911-4. doi: 10.1046/j.1365-2141.2001.02812.x.
7
Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss.
Am J Reprod Immunol. 1993 Mar;29(2):82-7. doi: 10.1111/j.1600-0897.1993.tb00570.x.
9
Risk factors for persistent positive anticardiolipin antibodies in women with recurrent pregnancy loss.
J Reprod Immunol. 2023 Mar;156:103920. doi: 10.1016/j.jri.2023.103920. Epub 2023 Feb 25.

引用本文的文献

1
Non-Criteria Obstetric Antiphospholipid Syndrome: Myth or Reality?
J Clin Med. 2025 Feb 15;14(4):1299. doi: 10.3390/jcm14041299.

本文引用的文献

1
2023 ACR/EULAR antiphospholipid syndrome classification criteria.
Ann Rheum Dis. 2023 Oct;82(10):1258-1270. doi: 10.1136/ard-2023-224609. Epub 2023 Aug 28.
6
EULAR recommendations for the management of antiphospholipid syndrome in adults.
Ann Rheum Dis. 2019 Oct;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213. Epub 2019 May 15.
7
The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases.
Autoimmun Rev. 2019 Apr;18(4):406-414. doi: 10.1016/j.autrev.2018.12.006. Epub 2019 Feb 15.
8
Obstetric antiphospholipid syndrome.
Lupus Sci Med. 2018 Sep 25;5(1):e000197. doi: 10.1136/lupus-2016-000197. eCollection 2018.
9
Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?
Nat Rev Rheumatol. 2018 Jul;14(7):433-440. doi: 10.1038/s41584-018-0032-6.
10
Diagnosis and Management of the Antiphospholipid Syndrome.
N Engl J Med. 2018 May 24;378(21):2010-2021. doi: 10.1056/NEJMra1705454.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验